PsiOxus - Model NG-350A - Single or Multi-Protein Therapeutics Medicine

This study will evaluate the safety, tolerability and preliminary efficacy of NG-350A in combination with a checkpoint inhibitor, in patients with advanced or metastatic epithelial tumors.

Our approach to treating cancer involves selective delivery of single or multi-protein therapeutics to tumors via an intravenously injected viral vector. These therapeutics act locally to reprogram the tumor microenvironment, providing new treatment options for patients with cancer.

Our novel class of medicines expand the potential of immunotherapy to applications beyond T cell-rich ‘hot’ tumors, with therapeutic potential as both single agent and in combination with current immuno-oncology agents